Literature DB >> 3332611

Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease.

C W Olanow1, M J Alberts.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3332611     DOI: 10.1097/00002826-198704000-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  4 in total

1.  Cost effectiveness of pramipexole in Parkinson's disease in the US.

Authors:  T J Hoerger; M V Bala; C Rowland; M Greer; E A Chrischilles; R G Holloway
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

Review 2.  Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Authors:  L M Rubenstein; A DeLeo; E A Chrischilles
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

Authors:  A Markham; P Benfield
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 6.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.